MBX Biosciences, Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.73M | 23.86M | 19.20M | 16.45M | 14.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 117.92M | 98.79M | 98.06M | 90.87M | 86.56M |
| Operating Income | -117.92M | -98.79M | -98.06M | -90.87M | -86.56M |
| Income Before Tax | -104.29M | -86.61M | -86.97M | -80.50M | -77.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -104.29 | -86.61 | -86.97 | -80.50 | -77.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.29M | -86.61M | -86.97M | -80.50M | -77.02M |
| EBIT | -117.92M | -98.79M | -98.06M | -90.87M | -86.56M |
| EBITDA | -117.66M | -98.56M | -97.81M | -90.62M | -86.29M |
| EPS Basic | -2.41 | -2.21 | -2.42 | -2.39 | -4.55 |
| Normalized Basic EPS | -1.56 | -1.44 | -1.59 | -1.58 | -2.92 |
| EPS Diluted | -2.41 | -2.21 | -2.42 | -2.39 | -4.55 |
| Normalized Diluted EPS | -1.56 | -1.44 | -1.59 | -1.58 | -2.92 |
| Average Basic Shares Outstanding | 173.34M | 159.09M | 145.92M | 134.45M | 106.77M |
| Average Diluted Shares Outstanding | 173.34M | 159.09M | 145.92M | 134.45M | 106.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |